Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors

Next Previous
X
Search
Trial Profile

Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CBP 501 (Primary) ; Cisplatin (Primary) ; Nivolumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Kidney-neoplasms; Liver cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors CanBas

    • Most Recent Events

    • 08 Mar 2021 Status changed from active, no longer recruiting to completed.
    • 28 Jan 2021 Planned End Date changed from 30 Mar 2020 to 17 Apr 2021.
    • 28 Jan 2021 Planned primary completion date changed from 31 Jan 2020 to 29 Mar 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top